Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: Insights derived from the FOURIER Trial

JAMA Cardiology

Volumn 2, Issue 12, 2017, Pages 1369-1374

  Arrieta, Alejandro ^a   Hong, Jonathan C ^b   Khera, Rohan ^c   Virani, Salim S ^d   Krumholz, Harlan M ^e   Nasir, Khurram ^f  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MIAMI CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPROTEIN CONVERTASE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH INSURANCE; HIDDEN MARKOV MODEL; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; FEMALE; HEART INFARCTION; HYPERCHOLESTEROLEMIA; INSURANCE; MALE; MARKOV CHAIN; MIDDLE AGED; MORTALITY; REIMBURSEMENT;

AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSURANCE; INSURANCE, HEALTH; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPROTEIN CONVERTASE 9; QUALITY-ADJUSTED LIFE YEARS; STROKE; UNITED STATES;

EID: 85033709553     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2017.3655     Document Type: Article

References (15)

1. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18): 1713-1722.
2. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743-753.
3. Arrieta A, Page TF, Veledar E, Nasir K. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One. 2017;12(1):e0169761.
4. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease [published online August 23, 2017]. JAMA Cardiol. doi:10.1001/jamacardio.2017.2762
5. Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the fourier trial. JAMA. 2017; 318(8):748-750.
6. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-753.
7. Centers for Disease Control and Prevention. Health Data Interactive. 2017. https://www.cdc.gov/nchs/hdi/. Accessed May 27, 2017.
8. Brønnum-Hansen H, Jørgensen T, Davidsen M, et al. Survival and cause of death aftermyocardial infarction: the Danish MONICA study. J Clin Epidemiol. 2001;54(12):1244-1250.
9. Brønnum-Hansen H, Davidsen M, Thorvaldsen P; Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke. 2001;32 (9):2131-2136.
10. Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J AmColl Cardiol. 2013;61(12):1250-1258.
11. Davis K, Carper K. Use and Expenses for Office-Based Physician Visits by Specialty, 2009: Estimates for the US Civilian Noninstitutionalized Population. Rockville, MD: Agency for Healthcare Research and Quality; August 2012. https://meps.ahrq.gov/data-files/publications/st381/stat381.pdf. Accessed September 13, 2017.
12. Bonafede MM, Johnson BH, Richhariya A, Gandra SR. Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia. Clinicoecon Outcomes Res. 2015;7:337-345.
13. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410-420.
14. Cutler DM, Gelber AM. Changes in the incidence and duration of periods without insurance. N Engl J Med. 2009;360(17):1740-1748.
15. Conti RM, Berndt ER. Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007. National Bureau of Economic Research Working Paper Series. 2014;No. 20016. http://www.nber.org/papers/w20016. Accessed September 13, 2017.